Alphatec (ATEC) to Release Earnings on Wednesday

Alphatec (NASDAQ:ATEC) is projected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Alphatec to post earnings of ($0.18) per share and revenue of $172.74 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Alphatec Price Performance

Shares of ATEC opened at $10.96 on Wednesday. The stock has a market capitalization of $1.55 billion, a P/E ratio of -8.56 and a beta of 1.43. Alphatec has a twelve month low of $4.88 and a twelve month high of $15.69. The company has a 50 day moving average of $10.39 and a 200-day moving average of $8.14. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Insider Activity

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at $5,379,750.81. This trade represents a 10.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total value of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at $66,020,580. This represents a 0.12 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 222,376 shares of company stock valued at $2,557,148. 22.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on ATEC. Needham & Company LLC raised their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.